Interní Med. 2016; 18(2): 91-94 | DOI: 10.36290/int.2016.022

Treating a type 2 diabetic patient with renal insufficiency

MUDr.Eva Račická
Diabetologická a interní ambulance, Ostrava

The treatment of type 2 diabetes mellitus is comprehensive where, in addition to recommendations on lifestyle modifications,

pharmacological treatment is initiated the range of which has expanded significantly in recent years. Metformin remains the firstchoice

drug and, according to disease progress, it is possible to choose combinations with other drugs. The present case report

describes the treatment in an obese type 2 diabetic patient who, at the time of diagnosis of his disease, was found to have stage 3

chronic kidney disease that is a contraindication to administering metformin. Following the compensation with insulin treatment,

the patient was commenced on linagliptin once daily that is only minimally eliminated by the kidneys; therefore, there is no need

for its reduction in renal insufficiency. The patient has been treated with linagliptin once daily as monotherapy safely and effectively

for three years while maintaining his weight and having no hypoglycaemias and no further worsening of renal insufficiency.

Keywords: type 2 diabetes mellitus, DPP-4 inhibitors, linagliptin, renal insufficiency

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Račická E. Treating a type 2 diabetic patient with renal insufficiency. Interní Med. 2016;18(2):91-94. doi: 10.36290/int.2016.022.
Download citation

References

  1. ČDS. Česká diabetologická společnost. Doporučený postup péče o diabetes mellitus 2. typu - 2016. Dostupné z www.diab.cz.
  2. Rychlík I, Francová L. Onemocnění ledvin u diabetiků, Postgraduální medicína, 2014; příloha 2, 23-30.
  3. Tesař V. Diabetická nefropatie: Diabetologie (pořadatel Škrha J), Galén 2009, 1. vydání.
  4. Al-Hwiesh AK, Abdul-Rahman IS, E-lDeen MA, et al. Metformin in peritoneal dialysis: A pilot expirience. Perit Dial Int. 2014; 34: 368-375. Go to original source... Go to PubMed...
  5. Pelikánová T, Bouček P. Léčba pacientů s diabetes mellitus 2. typu a renální insuficiencí. Farmakoterapie 2012; 8(1): 110-117.
  6. SPC linagliptin - dostupné z www.SUKL.cz
  7. SPC metformin - dostupné z www.SUKL.cz
  8. Hsu CY, Ordonez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008; 74: 101-107. Go to original source... Go to PubMed...
  9. Groop LP, Del Prato S, Taskinen MR, et al. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment, Diabetes, Obesity and Metabolism, 2014; 16: 560-568. Go to original source... Go to PubMed...
  10. McGill JB, Sloan L, Newman J, et al. Long-Term Efficacy and Safety of LInagliptin in Patients With Type2 Diabetes and Severe Renal Impairment: Diabetes Care, vol 36: 237-244.
  11. Scott D. Treatment of Type 2 diabetes in chornic kidney disease: A case for linafgliptin in the treatment of diabetes in severe renal impairment, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013; 6: 359-363. Go to original source... Go to PubMed...
  12. Scheen AJ. Pharmacokinetics and Clinical use of Inkretin-based Therapies in patients with Chronic Kidney Disease and Type 2 Diabetes.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.